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Abstract Heparinoids are used in the clinic as anticoagu-
lants. A specific pentasaccharide in heparinoids activates
antithrombin III, resulting in inactivation of factor Xa and–
when additional saccharides are present–inactivation of
factor IIa. Structural and functional analysis of the heteroge-
neous heparinoids generally requires advanced equipment, is
time consuming, and needs (extensive) sample preparation.
In this study, a novel and fast method for the characterization
of heparinoids is introduced based on reactivity with nine
unique anti-heparin antibodies. Eight heparinoids were
biochemically analyzed by electrophoresis and their reactiv-
ity with domain-specific anti-heparin antibodies was estab-
lished by ELISA. Each heparinoid displayed a distinct
immunoprofile matching its structural characteristics. The
immunoprofile could also be linked to biological character-
istics, such as the anti-Xa/anti-IIa ratio, which was reflected
by reactivity of the heparinoids with antibodies HS4C3
(indicative for 3-O-sulfates) and HS4E4 (indicative for
domains allowing anti-factor IIa activity). In addition, the
immunoprofile could be indicative for heparinoid-induced
side-effects, such as heparin-induced thrombocytopenia, as
illustrated by reactivity with antibody NS4F5, which defines
a very high sulfated domain. In conclusion, immunoprofiling
provides a novel, fast, and simple methodology for the
characterization of heparinoids, and allows high-throughput
screening of (new) heparinoids for defined structural and
biological characteristics.
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Introduction
Glycosaminoglycans (GAGs) are long, unbranched, nega-
tively charged polysaccharide chains. The precursor of
heparin and heparan sulfate (HS) is composed of alternating
N-acetylglucosamine (GlcNAc) and D-glucuronic acid
(GlcA) residues. In chondroitin sulfate (CS) and dermatan
sulfate (DS), the aminosugar is a N-acetylgalactosamine
(GalNAc) instead of GlcNAc. The polysaccharide chain
precursors are modified by a sequential series of enzymatic
reactions, including N-deacetylation/N-sulfation, C5-
epimerization of GlcA to L-iduronic acid (IdoA), and O-
sulfation at various positions [27, 32].
Heparin is widely used as an anticoagulant. A specific
pentasaccharide sequence (GlcNAc/NS(6OS)–GlcA–
GlcNS(3,6OS)–IdoA(2OS)–GlcNS(6OS)) [5, 23, 37]i n
heparin binds with high affinity to the enzyme inhibitor
antithrombin III, causing a conformational change, result-
ing in the exposition of its active sites and in inactivation of
factor Xa. For the inactivation of factor IIa, an additional
site in heparin proximal to the pentasaccharide is necessary.
The formation of a ternary complex between antithrombin
Glycoconj J (2008) 25:177–185
DOI 10.1007/s10719-007-9070-z
T. J. Wijnhoven: E. M. van de Westerlo:N. C. Smits:
J. F. Lensen: T. H. van Kuppevelt (*)
Department of Matrix Biochemistry,
Nijmegen Centre for Molecular Life Sciences,
P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
e-mail: A.vankuppevelt@ncmls.ru.nl
T. J. Wijnhoven: L. P. van den Heuvel
Department of Pediatric Nephrology,
Radboud University Nijmegen Medical Centre,
P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
A. L. Rops:J. van der Vlag:J. H. Berden
Nephrology Research Laboratory, Division of Nephrology,
Nijmegen Centre for Molecular Life Sciences,
Radboud University Nijmegen Medical Centre,
P.O. Box 9101, 6500 HB Nijmegen, The NetherlandsIII, factor IIa and heparin, which requires at least 18
saccharide residues for efficient formation, subsequently
results in the inactivation of factor IIa [23]. Next to heparin,
other heparinoids are used, including preparations contain-
ing other GAGs such as HS and DS, low molecular weight
heparins (LMWHs), and fondaparinux, a synthetic penta-
saccharide identical in structure to the antithrombin III-
binding pentasaccharide. Heparinoids are used to treat
patients with venous thrombosis and pulmonary embolism
[2, 5, 10, 22]. In addition, they are used to prevent
thrombosis in patients that undergo surgery and to prevent
clotting in the extracorporeal circulation during hemodi-
alysis [2, 5, 10, 22, 24, 28]. Due to their lower molecular
weight, LMWHs have a high anti-factor Xa activity
compared to their anti-factor IIa activity resulting in a more
refined regulation of coagulation [4, 24]. In addition, the
biological half-life of LMWHs/fondaparinux is longer in
comparison to heparin, and the incidence of heparin-
induced thrombocytopenia (HIT) is substantially reduced
[6, 7, 23].
LMWHs are synthesized from heparin by controlled
chemical or enzymatic depolymerization processes, result-
ing in the production of oligosaccharides of various lengths
(Table 1). Dalteparin and nadroparin are produced by
deamination using nitrous acid, resulting in the formation
of an unnatural 2,5-anhydromannitol residue at the reducing
end of the resulting oligosaccharides. Enoxaparin is
produced by chemical β-elimination at alkaline pH,
whereas tinzaparin is produced by enzymatic β-elimination
by heparinase. Both processes result in the formation of an
unsaturated uronic acid residue at the non-reducing end of
the GAG fragments [12, 17].
All heparinoids, with the exception of fondaparinux, are
heterogeneous mixtures of different GAG chains. Structural
analysis of heparinoids is generally done by nuclear
magnetic resonance spectroscopy, high pressure liquid
chromatography, mass spectrometry, capillary electropho-
resis, or polyacrylamide gel electrophoresis [17]. In general,
these techniques require sophisticated instrumentation and
sometimes extensive sample preparation. Alternative meth-
odologies that are fast and simple are needed. Immuno-
profiling of heparinoids could be a fast and simple method
to characterize the complex heparinoids. Recently, a
number of phage–display-derived antibodies were gener-
ated, reactive with various domain structures within
heparin. In this study nine antibodies–all defining different
heparin epitopes–were applied to study their reactivity with
heparinoids.
Materials and methods
Heparinoids
Thefollowingheparinoids wereincludedinthe study:heparin
(Sigma,St.Louis,MO),dalteparin(Pharmacia,Woerden,The
Netherlands), nadroparin (Sanofi-Synthélabo, Maassluis, The
Netherlands), enoxaparin (Aventis Pharma, Hoevelaken,
The Netherlands), tinzaparin (LEO Pharma, Breda, The
Netherlands), sulodexide (Alfa Wassermann S.p.A., Bologna,
Italy), danaparoid (Organon, Oss, The Netherlands), and
fondaparinux (Sanofi-Synthélabo, Maassluis, The Nether-
lands). Characteristics are given in Table 1.
Quantification of glycosaminoglycans by Farndale assay
A Farndale assay was done to determine the concentration
of GAGs in the preparations [13]. To 50 μl of the standard
(heparin, 0–100 μg/ml) and heparinoids 1 ml Farndale
reagent (40.5 mmol/l glycine, 40.6 mmol/l NaCl, and
0.05 mmol/l 1,9-dimethylmethylene blue, pH 3.0) was
added and absorbance was measured directly at 525 nm.
Table 1 Characteristics of therapeutic heparinoids
Heparinoid: generic name (brand name) Composition (and method of heparin modification) Molecular
weight, kDa
Heparin Heparin 5.0–30.0
Dalteparin (Fragmin) LMWH (deaminative cleavage with nitrous acid) 4.0–6.0
Nadroparin (Fraxiparine) LMWH (deaminative cleavage with nitrous acid) 2.4–7.2
Enoxaparin (Clexane, Lovenox) LMWH (β-eliminative cleavage by alkaline treatment) 3.5–5.5
Tinzaparin (Innohep, Logiparin) LMWH (β-eliminative cleavage by heparinase) 3.4–5.6
Sulodexide (Vessel Due F) 80% ‘fast-moving’ heparin
a, 20% DS <8.0
Danaparoid (Orgaran) 84% HS, 12% DS, 4% CS 4.0–10.0
Fondaparinux (Arixtra) Pentasaccharide: C31H43N3Na10S8 1,728
All drugs are derived from porcine intestinal mucosa, with the exception of the chemically synthesized pentasaccharide fondaparinux.
LMWH Low-molecular weight heparin, HS heparan sulfate, DS dermatan sulfate, CS chondroitin sulfate
aHeparin that is less sulfated and has a lower molecular weight [42].
178 Glycoconj J (2008) 25:177–185Determination of glycosaminoglycan classes by agarose gel
electrophoresis
The different classes of GAGs in the heparinoids were
separated by agarose gel electrophoresis, fixed in 0.1%
(w/v) azure A in 10 mmol/l MgCl2·6H2O, 50 mmol/l Na–
formiate and 0.001% (w/v)N a –azide (pH 3.5), and stained
by combined azure A–silver treatment [38].
Enzymatic digestion of heparinoids
Heparinoids were diluted in heparinase I digestion
buffer (50 mmol/l NaAc and 50 mmol/l Ca(Ac)2,
pH 7.0) and/or chondroitinase ABC digestion buffer
(25 mmol/l Tris and 2 mmol/l Mg(Ac)2,p H8 . 0 )t oaf i n a l
content of 4 mg/ml. The enzymes were added to a final
concentration of 0.02 IU/ml for heparinase I (E.C. 4.2.2.7;
from Flavobacterium heparinum; Seikagaku, Tokyo,
Japan) and 0.04 IU/ml for chondroitinase ABC (E.C.
4.2.2.4; from Proteus vulgaris; Sigma). Heparinase I
cleaves the linkages GlcNS±6S–IdoA2S predominantly
present in heparin and to a minor extent in HS [11].
Chondroitinase ABC cleaves CS and DS [11]. The
solutions were incubated for 16 h at 37°C.
Determination of glycosaminoglycan size
by polyacrylamide gel electrophoresis
Heparinoids and their enzymatic digestion products were
separated by polyacrylamide gel electrophoresis using a
33% gel [36], fixed in 0.8% (w/v) alcian blue in 2% (v/v)
HAc, and stained by combined azure A–silver treatment
[38].
Production of anti-heparin antibodies
Antibodies (Table 2) were obtained by biopanning against
HS or heparin, using bovine kidney HS (antibodies HS4C3
[41], HS3A8, HS4E4 [8], and LKIV69 [43]), porcine
intestinal mucosa heparin (antibodies EW3D10 and
EW4G2 [39]), human lung HS (antibody NS4F5; Smits et
al., unpublished results), and mouse and human skeletal
muscle GAG (antibodies AO4B08 and RB4EA12 [15],
respectively). Large scale production of soluble antibodies
was performed as described before [8, 41].
Enzyme-linked immunosorbent assay
Reactivity of the anti-heparin antibodies with the heparin-
oids was evaluated by enzyme-linked immunosorbent assay
(ELISA). Wells of microtiter plates were coated overnight
by incubation with the heparinoids that bound by passive
adsorption [41]. After blocking with PBS containing
3% (w/v) BSA and 1% (v/v) Tween-20 for 1 h, anti-heparin
antibodies [in PBS containing 1% (w/v)B S Aa n d0 . 1 %( v/v)
Tween-20] were added for 1.5 h. As a negative control,
antibody MPB49 was used, which is >95% identical to most
antibodies used, but does not bind any GAG. Bound
antibodies were detected using mouse IgG anti-VSV tag
antibody P5D4 (1:10; Boehringer Mannheim, Mannheim,
Germany), followed by incubation with alkaline phosphatase-
conjugated rabbit anti-mouse IgG (1:2,000; Dako, Glostrup,
Denmark), both for 1 h. Enzyme activity was detected using
100 μl1m gp-nitrophenyl phosphate (ICN, Aurora, OH)/ml
1 M diethanolamine/0.5 mM MgCl2 (pH 9.8) as a substrate.
Absorbance was measured at 405 nm [43]. Background
reactivity, measured with the control antibody MPB49, was
substracted. The absorbance with control antibody MPB49
was comparable to the absorbance measured when primary
antibody was omitted.
Immunofluorescence staining
Human kidney cryosections (2 μm) were incubated with
anti-heparin antibodies in the absence or presence of
100 μg/ml of the heparinoids. Bound antibodies were
detected as described [43].
Results
General biochemical analysis of heparinoids
The different classes of GAGs in the heparinoids were
separated by agarose gel electrophoresis (Fig. 1). Heparin
showed a band at about the same position as the HS
standard, whereas the LMWHs dalteparin, nadroparin,
enoxaparin, and tinzaparin migrated somewhat further into
the gel. Danaparoid displayed bands at the level of HS and
DS, whereas the CS band, which only represents 4% of the
prepration (Table 1), could not be detected. Sulodexide
clearly showed two bands, representing the ‘fast-moving’
heparin (heparin that is less sulfated and has a lower
molecular weight [42]) and DS fractions. The chemically
synthesized pentasaccharide fondaparinux, which has a
much lower molecular weight compared to the other
heparinoids, migrated further into the gel.
To analyze the molecular range of the heparinoids, gel
electrophoresis using 33% polyacrylamide was applied.
The LMWHs clearly displayed distinct fragments with a
lower molecular weight compared to heparin (Fig. 2a). The
smaller fragments of enoxaparin compared to tinzaparin
(both prepared by β-elimination) can be explained by a
preference of heparinase for 2-O-sulfated iduronic acid in
contrast to chemical alkaline treatment, which results in
cleavage at both sulfated and non-sulfated iduronic acid
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with less distinct fragments, in line with their methods of
preparation, which does not include a specific depolymer-
ization step. The pentasaccharide fondaparinux demonstrat-
ed primarily one individual band. To further establish the
nature of the heparinoids, they were subjected to enzymatic
digestion using heparinase I and/or chondroitinase ABC
(Fig. 2b for dalteparin, enoxaparin, and sulodexide).
Heparin, dalteparin, nadroparin, enoxaparin, tinzaparin,
and fondaparinux were only cleaved by heparinase I, in
accordance with their derivation from heparin. Sulodexide
was cleaved by heparinase I as well as chondroitinase ABC,
which is in line with the heparin/DS nature of the
preparation. Danaparoid was primarily cleaved by chon-
droitinase ABC, reflecting the presence of DS/CS, whereas
heparinase I was less effective.
Characterization of heparinoids using anti-heparin
antibodies
Reactivity of anti-heparin antibodies with immobilized
heparinoids was analyzed by ELISA (Table 3). For
Table 2 Characteristics of epitope-specific anti-heparin antibodies
Antibody VH CDR3
sequence
VH
family
DP
gene
GAG used for
selection
Essential modifications Inhibitory
modifications
HS4C3 GRRLKD 3 38 Bovine kidney HS [41] N-sulfation
2-O-sulfation (minor
importance)
6-O-sulfation
3-O-sulfation
HS3A8 GMRPRL 3 38 Bovine kidney HS [8] N-sulfation
C5-epimerization
2-O-sulfation
6-O-sulfation (likely)
HS4E4 HAPLRNTRTNT 3 38 Bovine kidney HS [8] N-acetylation 2-O-sulfation
a
6-O-sulfation N-sulfation
C5-epimerization
LKIV69 GSRSSR 3 38 Bovine kidney HS [43] N-sulfation 6-O-sulfation
C5-epimerization (likely)
2-O-sulfation
EW3D10 GRTVGRN 3 38 Porcine intestinal mucosa
heparin [39]
Sulfation required, position(s)
unknown
b
EW4G2 GKVKLPN 3 38 Porcine intestinal mucosa
heparin [39]
Sulfation required, position(s)
unknown
b
NS4F5 SGRKGRMR 3 53 Human lung HS
c N-sulfation
C5-epimerization
2-O-sulfation (high)
6-O-sulfation (high)
AO4B08 SLRMNGWRAHQ 3 47 Mouse skeletal muscle
GAG [15]
N-sulfation
C5-epimerization
2-O-sulfation
d
6-O-sulfation (high)
RB4EA12 RRYALDY 3 32 Human skeletal muscle
GAG [15]
N-acetylation
N-sulfation
6-O-sulfation
MPB49
(control)
WRNDRQ 3 38 ––
Given are the antibody name, amino acid sequence of the VH complementary determining region 3 (CDR3), VH germ line gene family, DP gene
number, selection moiety, and relevant modification reactions required for antibody binding. Table derived from Wijnhoven et al. unpublished
results.
GAG Glycosaminoglycan, HS heparan sulfate
aAntibody HS4E4 possibly requires as yet unspecified O-sulfated residues [16].
bAlthough the chemical nature of the specific heparin/HS structure recognized is not exactly known, the antibody defines a unique sulfated
heparin/HS structure as demonstrated by its specific staining pattern on renal cryosections [8, 39].
cSmits et al., unpublished results
dAntibody AO4B08 requires an internal 2-O-sulfated iduronic acid residue [16].
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100%. A distinct antibody-binding profile could be ob-
served for all antibodies, although also similar reactivity with
a number of antibodies was noticed. For instance, enoxaparin
and tinzaparin, both prepared by β-elimination, reacted
differently with antibodies LKIV69 and EW4G2, whereas
they reacted similarly with the other antibodies. Nadroparin
reacted very poorly with all the antibodies tested, which may
beinlinewithitsoveralllowamountofsulfateddisaccharides
in comparison with other LMWHs [17]. In contrast,
sulodexide and danaparoid reacted strongly with antibody
HS4E4, which defines a low-sulfated and N-acetylated
epitope, in comparison to the LMWHs. This is in line with
the presence of low-sulfated heparin (HS) and HS in
sulodexide and danaparoid, respectively, and which contain
a substantial amount of N-acetylated glucosamine. Compared
to heparin, the other heparinoids reacted poorly with
antibody NS4F5, which defines a very highly sulfated
oligosaccharide.
Heparinoids could be ranked according to their reactivity
with antibodies. For instance, reactivity of antibody
EW4G2 was highest with heparin and sulodexide, followed
by tinzaparin, dalteparin, and enoxaparin. Reactivity with
the other heparinoids was very low or absent. Antibody
LKIV69 reacted strongly with heparin, followed by
sulodexide and tinzaparin, whereas other heparinoids
reacted poorly. Reactivity of antibody AO4B08 was highest
with heparin and sulodexide, followed by danaparoid and
enoxaparin/tinzaparin/dalteparin, whereas reactivity with
nadroparin was absent. These data indicate that distinct
heparin domain structures are present in different commer-
cially available heparinoids.
The only chemically defined heparinoid studied was the
pentasaccharide fondaparinux (GlcNS(6OS)–GlcA–GlcNS
(3,6OS)–IdoA(2OS)–GlcNS(6OS)). Due to its small size
(1,728 kDa), it was assayed using a competition ELISA
(Table 4). Heparin was included as a reference and values
obtained for fondaparinux were related to those obtained
for heparin. Antibodies HS4E4 and RB4EA12, both
requiring N-acetylation in their epitopes, did not react with
fondaparinux. Antibody NS4F5, which reacts with an
extremely high sulfated oligosaccharide, was also not
reactive. These results are in line with the chemical
composition of fondaparinux, which contains no N-
acetylated glucosamine and a non-sulfated glucuronic acid
residue. Reactivity with antibody LKIV69, which reacts
poorly with 6-O-sulfated epitopes, was very weak and
reflects the high amount of 6-O-sulfation in fondaparinux.
Reactivity with antibody AO4B08, which needs C5-
epimerization, N-sulfation, high 6-O-sulfation and an
internal 2-O-sulfated iduronic acid residue, was only
moderate/poor, reflecting the lack of an internal 2-O-
sulfated iduronic acid (i.e. flanked by other iduronic acid
residues). Reactivity with antibody HS4C3, which requires
N-, 3-O-, and 6-O-sulfation, and antibody HS3A8, which
requires at least C5-epimerization and N- and 2-O–
sulfation, was high, which corresponds with the chemical
structure of fondaparinux. Reactivity was also high with
antibodies EW3D10 and EW4G2, both defining an as yet
undefined, but sulfated oligosaccharide. These data indicate
that reactivity with antibodies may provide some chemical
information of heparinoids.
Reactivity of the anti-heparin antibodies with immobi-
lized heparinoids was supported by immunofluorescence
analysis (Fig. 3). When human renal cryosections were
Fig. 1 Agarose gel electrophoresis of heparinoids. The different
classes of GAGs in the drugs were visualized by a combined azure
A–silver staining procedure. The standard contains 40 ng HS, 20 ng
DS, and 20 ng CS
Fig. 2 Thirty-three percent polyacrylamide gel electrophoresis of
undigested (a) and enzymatically digested (b) heparinoids. Heparin-
oids were visualized by a combined alcian blue-silver staining
procedure. Treatment with heparinase I resulted in cleavage of
dalteparin and enoxaparin, whereas treatment with chondroitinase
ABC did not. Sulodexide was cleaved by heparinase I as well as
chondroitinase ABC
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heparinoids, staining was completely abolished with those
heparinoids, which reacted strongly with the antibodies in
ELISA (e.g. heparin and sulodexide for antibodies HS4C3
and HS4E4). An obvious decreased staining was noticed
for those heparinoids, which reacted moderately with the
antibodies (e.g. nadroparin for antibody HS4C3), whereas
no major differences in staining were observed for those
heparinoids, which did not bind to antibodies (e.g.
nadroparin for antibody HS4E4).
Discussion
In this study eight heparinoids were characterized by their
reactivity with nine different anti-heparin antibodies. All
heparinoids showed a distinct antibody-binding profile in
line with differences in GAG composition (heparin, HS,
CS, DS), molecular weight, and method of preparation. A
number of antibodies reacted strongly with certain heparin-
oids, but not with others. It may therefore be possible to
deduce chemical and biological information of a specific
heparinoid by virtue of its antibody profile. For instance,
antibody NS4F5 showed reactivity with only heparin. This
antibody defines a stretch of trisulfated (N-, 2-O-, and 6-O-
sulfated) and epimerized disaccharides and therefore
defines a highly sulfated heparin domain (Smits et al.,
unpublished results). The lack of reactivity of the other
heparinoids for NS4F5 indicates the absence or the
destruction of the domain during their preparation. Absence
may hold for sulodexide and danaparoid, which contain HS
rather than heparin. Destruction by the depolymerization
processes may hold for the LMWHs. In this respect,
reactivity with antibody NS4F5 may be indicative for the
degree of depolymerization. The antibody profile of the
chemically synthesized pentasaccharide fondaparinux is
compatible with its chemical structure GlcNS(6OS)–
GlcA–GlcNS(3,6OS)–IdoA(2OS)–GlcNS(6OS). Reactivity
with antibodies HS4C3 and HS3A8 indicates it to contain
iduronic acid and N-, 2-O-, 3-O-, and 6-O-sulfate residues,
whereas poor/no reactivity with antibodies HS4E4,
LKIV69, AO4B08, and RB4EA12 indicates the lack of
internal 2-O-sulfated iduronic acid residues (i.e. flanked by
other iduronic acids) and N-acetylated glucosamine resi-
dues. Lack of reactivity with antibody NS4F5 indicates that
fondaparinux does not contain a stretch of tri-sulfated
disaccharides.
Next to information on the chemical properties of the
heparinoids, the antibody profile may be indicative for their
biological activity, e.g. the anti-Xa/anti-IIa ratio. This ratio
is of essential importance since it is associated with a more
predictable anticoagulant effect. The anti-Xa/anti-IIa ratio is
1 for unfractionated heparin, 2–4 for LMWHs, 0.5 for
sulodexide, and infinite for fondaparinux [2, 23]. Anti-
bodies such as HS4E4 and AO4B08 (Tables 3 and 4),
which are highly reactive with heparin and sulodexide, but
poorly/not with LMWHs and fondaparinux, likely bind to a
heparin domain structure at a site proximal to the
Table 3 Reactivity of anti-heparin antibodies with heparinoids (ELISA)
HS4C3 HS3A8 HS4E4 LKIV69 EW3D10 EW4G2 NS4F5 AO4B08 RB4EA12
Heparin 100 100 100 100 100 100 100 100 100
Dalteparin 75±6 44±4 8±5 3±1 33±6 49±8 0±0 16±4 13±2
Nadroparin 29±3 5±2 4±3 0±0 3±1 7±4 0±0 1±1 1±1
Enoxaparin 80±9 56±8 7±3 10±2 36±8 26±7 1±1 28±7 21±6
Tinzaparin 84±1 55±2 8±3 44±10 45±12 74±1 9±2 20±3 25±8
Sulodexide 102±5 71±11 283±21 51±7 43±10 100±3 0±0 102±15 26±8
Danaparoid 69±11 22±3 58±17 2±2 2±1 1±1 0±0 63±6 3±1
Anti-heparin antibodies were applied to heparinoids immobilized on microtiter plates. Given is the reactivity of the antibodies with the
heparinoids relative to unmodified heparin. Values are given as mean ± SEM (n=4). Each hepainoid shows a distinct immunoprofile.
Table 4 Reactivity of anti-heparin antibodies with heparin and fondaparinux (competition ELISA)
HS4C3 HS3A8 HS4E4 LKIV69 EW3D10 EW4G2 NS4F5 AO4B08 RB4EA12
Heparin 0.3±0.1 0.4±0.1 2.7±0.1 0.2±0.0 0.1±0.0 0.1±0.0 0.1±0.0 1.2±0.2 <0.01
Fondaparinux 1.7±0.2 1.3±0.1 >200 10.3±0.8 0.2±0.0 1.5±0.5 11.7±0.8 12.3±3.8 21.5±0.5
Ratio fondaparinux/heparin 5.7 3.3 >74 51.5 2 15 117 10.3 >2150
Given are the amounts of heparinoids (micrograms per milliliter), which result in a 50% inhibition of the binding of the anti-heparin antibodies to
immobilized HS/heparin (IC50 values), and the ratio between antibody reactivity with fondaparinux and heparin. Values are given as mean ± SEM
(n=3). Antibody EW3D10 showed a strong reactivity with fondaparinux, followed by antibodies HS4C3, HS3A8, and EW4G2. The other
antibodies showed a relatively weak or no reactivity.
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anti-factor IIa activity. These results indicate that when a
heparinoid is recognized by antibodies HS4C3, HS3A8,
EW3D10, and EW4G2 (which showed a high reactivity
with fondaparinux; Table 4), as well as by antibodies
HS4E4 and AO4B08, the heparinoid is able to form a
ternary complex with antithrombin III and factor IIa,
resulting in inactivation of both factors Xa and IIa [23].
On the other hand, when a heparinoid is recognized by
antibodies HS4C3, HS3A8, EW3D10, and EW4G2, but not
by antibodies HS4E4 and AO4B08, it is does not contain
the heparin domain structure at the site proximal to the
pentasaccharide required for factor IIa binding. In this case
only factor Xa will be inactivated. When a ratio is
calculated from reactivity of heparinoids with antibodies
HS4C3 and HS4E4 (indicative for 3-O-sulfates and for the
presence of domains allowing IIa activity, respectively),
and heparin is assigned a ratio of 1, the following numbers
are found: dalteparin, 9; nadroparin, 7; enoxaparin, 11;
tinzaparin, 11; sulodexide, 0.4; and fondaparinux, >>13 (no
antibody HS4E4 reactivity observed). These numbers are in
line with the above mentioned anti-Xa/anti-IIa ratios, which
were determined by enzymatic assays [2, 23], and indicate
that biological characteristics are associated with antibody
profiles.
Heparin-induced thrombocytopenia (HIT) is a major
complication in patients administered heparin. Heparin
binding to platelet factor 4 (PF4) causes a conformational
change in the protein, rendering it antigenic. Susceptible
patients develop antibodies to the heparin-PF4 complex,
and binding of the antibody-PF4-heparin complex to its
receptor on platelets results in platelet activation and
aggregation. In addition, platelets are removed by activated
immune cells, resulting in thrombocytopenia [6]. Highly
sulfated domains within heparin/HS are involved in the
binding to PF4 [31], and an increase in sulfation and size is
associated with an increased risk of HIT [6, 19]. This may
explain why the incidence of HIT is lower in patients
treated with LMWHs, danaparoid, or fondaparinux com-
pared to unfractionated heparin [7, 23]. Antibody NS4F5,
which defines a highly sulfated domain, reacted strongly
with heparin, but not with the other heparinoids. Reactivity
with this antibody may thus be used to obtain information
about the risk of a heparinoid to induce HIT.
Although we have focussed here on the immunoprofiling
of heparinoids in the context of anticoagulation, this
technique may also be useful to evaluate heparinoids in
other settings. Heparin and LMWHs have been used to treat
patients with kidney disease since an ameliorating effect on
a.o. proteinuria has been found [1, 14, 21, 25, 30, 33, 34,
40]. Likewise, heparinoids are reported to have anti-tumor
and anti-metastatic effects [3, 20, 29] ,t h ed e g r e eo f
sulfation being of crucial importance. Heparinase III-
digested heparin (highly sulfated fragments), inhibited
tumor growth, whereas heparinase I-digested heparin (low
sulfated fragments) promoted tumor growth [18], under-
scoring the necessity to characterize the preparation used.
In addition to the implementation of these antibodies to
characterize the therapeutic potential of heparinoids, they
may be used to stage a disease (e.g. kidney disease, cancer)
characterized by a specific HS profile in tissue, blood, and/
or urine.
Since the antibody profile of the heparinoids used in
these studies may be correlated to a specific biological
effect, antibodies may be used for the identification and
subsequent characterization of the active structures within
the heparinoids, which may result in the development of
more specific drugs. The antibodies described here may
also be used to counteract bleeding in patients administered
an overdose of heparinoids. This is generally accomplished
Fig. 3 Immunofluorescence staining of human renal cryosections with
anti-heparin antibodies HS4C3 and HS4E4 in the absence and
presence of heparinoids. Staining was abolished when renal cryosec-
tions were incubated with HS4C3 or HS4E4 in the presence of heparin
or sulodexide. HS4C3 staining was decreased in the presence of
nadroparin, whereas HS4E4 staining was unaffected. Bar represents
50 μm; magnification is identical for each photograph. G Glomerulus,
BC Bowman’s capsule, T renal tubule
Glycoconj J (2008) 25:177–185 183by treatment with protamine sulfate [9, 26], but this rather
unspecific polycation may cause hypotension, bradycardia,
and thrombocytopenia. In addition it may cause other
severe side effects including anaphylactic and anaphylac-
toid reactions, resulting in respiratory distress, circulatory
collapse, capillary leak, and pulmonary hypertension [26].
There is a need for safer agents that inhibit the anticoag-
ulant activity of heparinoids, and some antibodies described
here may be useful, especially those that also react with
fondaparinux, which is difficult to inhibit in vivo. It has
already been described that antibodies HS4C3 and
EW3D10 strongly inhibited heparin-induced anticoagula-
tion (APTT clotting assay) [35, 39]. Antibody HS4C3 also
blocked the anticoagulant activities of heparin and fonda-
parinux in an anti-factor Xa assay [35]. These studies
indicate that anti-heparin antibodies may react with
heparinoids thereby neutralizing their anticoagulant effect.
Finally, our antibodies may be used for fast industrial
screening of heparinoids. A quality check of heparinoid
batches may be performed using the antibodies since each
heparinoid shows a specific immunoprofile.
In conclusion, this study presents a novel way of
characterizing heparinoids using immunoprofiling. Reactiv-
ity with antibodies was found indicative for chemical and
biological aspects of the heparinoids, and may therefore be
used for a fast and simple screening of industrial batches for
defined characteristics.
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